What Will the FDA Approval of Sun Pharma’s Alopecia Drug Mean for Patients?

July 29, 2024

It’s a “Three-Peat”: FDA Approves LEQSELVI (Deuruxolitinib) for the Treatment of Severe AA

July 26, 2024

Mount Sinai Secures Large NIH Grant to Study JAK Inhibition in People with Down Syndrome and AA or AD

July 11, 2024

ICYMI: Revolutionizing Alopecia Areata Recap With Brett King, MD, PhD

June 21, 2024

Permanent Makeup in Dermatology: New Report Reviews Techniques, Regulations, and Risks

June 18, 2024

AA Pipeline Update: Equillium’s EQ101 Shows Promise in Phase 2 Trial

June 5, 2024

Soterios Pharma’s STS-01 Meets Efficacy Endpoints in AA Trial

May 31, 2024

Mount Sinai Awarded $6.6M NIH Grant to Study Dupilumab in Pediatric AA

May 16, 2024

Drug-delivering Microneedle Patch May Spur Hair Regrowth in AA

May 9, 2024

Study: Stigma Affects Quality of Life for Kids With Chronic Skin Diseases

April 24, 2024

Topical Vs. Oral Minoxidil: What’s the Difference for Men With Androgenetic Alopecia?

April 15, 2024

Real-world Data: AA Patients Report Unmet Needs, High Disease Burden

March 8, 2024